Nike (NYSE:NKE) , a designer of athletic footwear, apparel, and equipment, closed Thursday at $44.19, down 1.00%. The stock remains under pressure as analysts weigh its recent profit decline, a weak revenue outlook, and softness in China. Trading volume reached 59.4 million shares, coming in about 220% above its three-month average of 18.5 million shares. Nike IPO'd in 1980 and has grown 24,490% s...
Nike (NYSE:NKE) , a designer of athletic footwear, apparel, and equipment, closed Thursday at $44.19, down 1.00%. The stock remains under pressure as analysts weigh its recent profit decline, a weak revenue outlook, and softness in China. Trading volume reached 59.4 million shares, coming in about 220% above its three-month average of 18.5 million shares. Nike IPO'd in 1980 and has grown 24,490% since going public. The S&P 500 edged up 0.09% to 6,582, while the Nasdaq Composite added 0.18% to finish at 21,879. Within the athletic footwear and apparel industry, peers Adidas closed at $78.13 (-1.67%) and Puma finished at $2.48 (-4.62%), reflecting continued pressure across global sportswear brands. In the two trading days following Nike’s Q3 earnings report, the sportswear giant has seen over 20 analysts cut their price targets on the company’s stock. Wall Street’s concerns include: Continue reading
songqiuju/iStock via Getty Images The last article on Texas Pacific Land Corporation ( TPL ) mentioned that the stock was extremely expensive for the growth characteristics of the company. Since then, the Iran situation that includes effectively closing the Strait of Hormuz has basically sent everything in the industry much higher. However, such issues rarely last long. Because the price-earnings ...
songqiuju/iStock via Getty Images The last article on Texas Pacific Land Corporation ( TPL ) mentioned that the stock was extremely expensive for the growth characteristics of the company. Since then, the Iran situation that includes effectively closing the Strait of Hormuz has basically sent everything in the industry much higher. However, such issues rarely last long. Because the price-earnings ratio remains very high, this particular idea has a lot more downside potential when things settle down than do many of my other choices. Stock Price The last article showed the Quant system ranking this as a Strong Sell. But the Iranian situation changed that ranking because of the stock price action. The Quant system now has the stock as a Hold. Texas Pacific Land Corporation Common Stock Price History And Key Valuation Measures (Seeking Alpha Website April 2, 2025) It is very easy to see the effect that the Iranian situation has had on the stock price from the chart above. That was definitely an unknown at the time the last article was written. However, this is not an industry that is known for price-earnings ratios of 52 for really much of any reason. This stock has long been an exception to much of the industry. As such, it is really just a question as to when the stock price will value the business in the same fashion as much of the rest of the industry. Pricing like this can persist for a while. The Iranian situation is far from settled. Therefore, commodity prices can go a lot higher before they inevitably decline. The timing of anything in the future is very much unsettled right now in the eyes of the market. The Business The company has two main revenue streams currently with some future possibilities. The land it has it farms out on a royalty basis to form one main revenue stream. This business is basically an upstream business without the major risks of upstream like dry holes or the expenses of drilling and completion. The company largely makes its money as a p...
Ambev (NYSE:ABEV) produces and sells beer and soft drinks in the Americas. Shares closed at $2.93, down 1.35%. The stock moved without any company-specific catalysts today, but investors are watching analyst ratings and capital returns for future direction. Trading volume reached 42.3 million shares, coming in about 71% above compared with its three-month average of 24.7 million shares. Ambev IPO'...
Ambev (NYSE:ABEV) produces and sells beer and soft drinks in the Americas. Shares closed at $2.93, down 1.35%. The stock moved without any company-specific catalysts today, but investors are watching analyst ratings and capital returns for future direction. Trading volume reached 42.3 million shares, coming in about 71% above compared with its three-month average of 24.7 million shares. Ambev IPO'd in 1997 and has grown 552% since going public. The S&P 500 (SNPINDEX:^GSPC) inched up 0.11% to 6,583, while the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 0.18% to finish at 21,879. Among beverage maker/brewers, industry peer Anheuser-Busch InBev/NV (NYSE:BUD) closed at $71.30, rising 0.75% as investors compare global brand strength and exposure to premium brands as consumers tighten wallets. Ambev had no new company-specific headlines today, but investors are still digesting some news from the board of directors meeting held on March 30. In that meeting the board approved 2025 profit allocation and suggested 2026 salary limits, amendments to the bylaws, and a capital increase driven by stock options. Continue reading
Judge Lewis Liman dismissed 10 of Lively’s 13 claims against Baldoni, including claim of sexual harassment Sign up for the Breaking News US email to get newsletter alerts in your inbox A federal judge has thrown out the majority of Blake Lively ’s claims against Justin Baldoni. In a court ruling on Thursday, Judge Lewis Liman dismissed 10 of the 13 claims in Lively’s lawsuit against her co-star an...
Judge Lewis Liman dismissed 10 of Lively’s 13 claims against Baldoni, including claim of sexual harassment Sign up for the Breaking News US email to get newsletter alerts in your inbox A federal judge has thrown out the majority of Blake Lively ’s claims against Justin Baldoni. In a court ruling on Thursday, Judge Lewis Liman dismissed 10 of the 13 claims in Lively’s lawsuit against her co-star and director of the domestic violence film It Ends With Us . Continue reading...
New tax will hit branded drugs and active ingredients while exempting generics for at least one year Sign up for the Breaking News US email to get newsletter alerts in your inbox Donald Trump is threatening 100% tariffs on pharmaceutical companies that have not struck deals to lower US drug prices. The new tariff will only apply to branded drugs and their active ingredients. Generic drugs, which m...
New tax will hit branded drugs and active ingredients while exempting generics for at least one year Sign up for the Breaking News US email to get newsletter alerts in your inbox Donald Trump is threatening 100% tariffs on pharmaceutical companies that have not struck deals to lower US drug prices. The new tariff will only apply to branded drugs and their active ingredients. Generic drugs, which make up more than 90% of medicines sold in the US, will be exempted from tariffs for at least one year. Orphan, veterinary and other specialty drugs are exempt if they are from trade deal countries or meet urgent public health needs. Continue reading...
raisbeckfoto Starbucks ( SBUX ) has closed its deal with Boyu Capital to transfer control of its China operations, the company said on Thursday. Under the terms of the agreement, funds managed by Boyu Capital now hold a 60% stake in Starbucks China's retail operations, while Starbucks retains a 40% ownership interest. The latter continues to own and license the brand and intellectual property to t...
raisbeckfoto Starbucks ( SBUX ) has closed its deal with Boyu Capital to transfer control of its China operations, the company said on Thursday. Under the terms of the agreement, funds managed by Boyu Capital now hold a 60% stake in Starbucks China's retail operations, while Starbucks retains a 40% ownership interest. The latter continues to own and license the brand and intellectual property to the joint venture. The alliance, which currently oversees around 8,000 company-operated coffeehouses, will transition to a licensed operating model, aiming to grow to as many as 20,000 locations over time, the company said. "The joint venture is designed to enhance Starbucks' ability to expand its footprint, deepen local relevance, and elevate the customer experience while maintaining the integrity of its brand and values," the Seattle-based coffee company added. The deal was announced in November 2025. The company had then said that Boyu would acquire its interest based on a cash-free, debt-free enterprise value of ~$4 billion. Starbucks had projected its China retail business to be valued at more than $13 billion, comprising proceeds from the sale of a controlling stake in the partnership to Boyu, the value of its retained interest, and the net present value of licensing income payable over the next decade or longer. SBUX -0.40 % after hours to $ 90. Source: Press Release More on Starbucks Starbucks: The Financial Brew Sours Starbucks Corporation (SBUX) Shareholder/Analyst Call - Slideshow Starbucks: Full Price For A Half-Brewed Turnaround Starbucks is giving employees new incentives to improve customer service Highlights from Starbucks' annual meeting
Many tech stocks have moved lower, along with the tech-heavy Nasdaq Composite , in recent months. This is partly because there are growing fears of a recession. While some beaten-down companies could eventually bounce back -- making them worth sticking with for those with a long investment horizon -- some investors are choosing to rotate their cash into more stable companies, perhaps because they ...
Many tech stocks have moved lower, along with the tech-heavy Nasdaq Composite , in recent months. This is partly because there are growing fears of a recession. While some beaten-down companies could eventually bounce back -- making them worth sticking with for those with a long investment horizon -- some investors are choosing to rotate their cash into more stable companies, perhaps because they are relatively close to retirement and are looking to avoid significant volatility. For investors on the hunt for more stable stocks, let's consider two in the healthcare sector that may be worth buying right now: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) . Image source: Getty Images. Continue reading